ArticleJournal of oncology practice2018
What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?
Article in Journal of oncology practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods.European radiology · 2026Pooled it
- ISUOG/ESGO Consensus Statement on ultrasound-guided biopsy in gynecological oncology.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2025Guideline
- Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.JCO precision oncology · 2021Trial
- Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.PloS one · 2019Trial
- Perspectives From an Expert-Guided Discussion on Maximizing the Research Potential of Small Biopsy Tissue.JCO precision oncology · 2026Article
- Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors.Cancer chemotherapy and pharmacology · 2026Article
- Article
- Experts' attitudes towards 'targeted autopsies' using qualitative interviews in a medical network in Germany.BMJ open · 2025Article
- Novel Biopsy Gun Impacts Biopsy Sample Quality and Quantity.Cardiovascular and interventional radiology · 2025Article
- TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial.Journal for immunotherapy of cancer · 2025Article
- Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial Teams.Journal of clinical medicine · 2024Article
- Companion diagnostic requirements for spatial biology using multiplex immunofluorescence and multispectral imaging.Frontiers in molecular biosciences · 2023Review
- An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.The oncologist · 2022Article
- Label-free multimodal nonlinear optical imaging of needle biopsy cores for intraoperative cancer diagnosis.Journal of biomedical optics · 2022Article
- Review
- T-Cell Heterogeneity in Baseline Tumor Samples: Implications for Early Clinical Trial Design and Analysis.Frontiers in immunology · 2022Article
- Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy.Therapeutic advances in medical oncology · 2022Article
- Variability in biopsy quality informs translational research applications in hepatocellular carcinoma.Scientific reports · 2021Article
- An analysis of research biopsy core variability from over 5000 prospectively collected core samples.NPJ precision oncology · 2021Article
- Rapid non-destructive volumetric tumor yield assessment in fresh lung core needle biopsies using polarization sensitive optical coherence tomography.Biomedical optics express · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purpose: Research biopsy specimens collected in clinical trials often present requirements beyond those of tumor biopsy specimens collected for diagnostic purposes. Research biopsies underpin hypothesis-driven drug development, pharmacodynamic assessment of molecularly targeted anticancer agents, and, increasingly, genomic assessment for precision medicine; insufficient biopsy specimen quality or quantity therefore compromises the scientific value of a study and the resources devoted to it, as well as each patient's contribution to and potential benefit from a clinical trial.
methods: To improve research biopsy specimen quality, we consulted with other translational oncology teams and reviewed current best practices.
results: Among the recommendations were improving communication between oncologists and interventional radiologists, providing feedback on specimen sufficiency, increasing academic recognition and financial support for the time investment required by radiologists to collect and preserve research biopsy specimens, and improving real-time assessment of tissue quality.
conclusion: Implementing these recommendations at the National Cancer Institute's Developmental Therapeutics Clinic has demonstrably improved the quality of biopsy specimens collected; more widespread dissemination of these recommendations beyond large clinical cancer centers is possible and will be of value to the community in improving clinical research and, ultimately, patient care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.